Espiride 5 ml Capsule
PDF Leaflet Revision Date: 14 April 1998
Clinical Summary
Quick overview from the medicine insert
Indication
Management of schizophrenia and reactive depression.
Dosage (summary)
Adults: 200-400 mg twice daily, max 1.2 g; Maintenance: 600-800 mg/day.
Onset of Action / Duration
Onset: 1-2 weeks, Duration: 7-9 hours
Special Populations
- Elderly
- Debilitated patients
- Patients with liver dysfunction
Pregnancy & Breastfeeding
Safety in pregnancy not established; use caution in breastfeeding.
Key Drug Interactions
- Anticholinergics
- CNS depressants
- Antacids
Contraindications
- Sensitivity to sulpiride
- Phaeochromocytoma
- Acute porphyria
Common side effects
- Sedation
- Extrapyramidal disorders
- Hypertension
- Weight gain
Counselling Points
- Avoid alcohol
- Monitor for mood changes
- Do not operate machinery
Serious warnings
- Caution in cardiovascular disease
- Risk of agranulocytosis
- Withdrawal symptoms
Important Disclaimer
The Espiride 5 ml Capsule professional information leaflet below is the property of Pharmacare and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
